In patients with low serum AFP levels, patients with high serum myostatin levels had a significantly higher HCC risk than those with low serum myostatin levels (HR 9.12, 95% CI 4.25–19.57, p < 0.001). This evidence concerns the gene MSTN and hepatocellular carcinoma.